Article

Mylan Launches Generic High Cholesterol Drug

Generic version of fenofibrate (Fenoglide) tablets was approved by the FDA on July 6, 2016.

Mylan is releasing a generic version of Santarus’ fenofibrate (Fenoglide) tablets.

The FDA approved the manufacturer’s abbreviated new drug application for the 40-mg and 120-mg tablets on July 6, 2016. The product may be used as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, and apolipoprotein B and to increase high-density lipoprotein in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

In the year ending April 30, 2016, fenofibrate tablets had US sales of around $28.6 million, IMS Health reported. Mylan hopes to receive FDA approval for nearly 250 additional abbreviated new drug applications still pending.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
5 experts in this video